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enopause and
ardiovascular Risk
ause or Consequence?*
era Bittner, MD, MSPH, FACC
irmingham, Alabama
n the developed world, mean life expectancy for women
ince 1900 has increased from 50.0 to 81.7 years (1). Given
n average age at menopause of 51.4 years, women in
eveloped countries thus live over one-third of their lives
n the postmenopausal state (2). Although life expectancy at
irth varies by country owing to varying rates of infant and
hild mortality, life expectancy for women at age 50 years is
uite similar throughout the world (range 27 to 32 years)
3). Global population projections predict a marked increase
n the number of postmenopausal women from 467 million in
990 to 1,200 million in 2030 (3). Understanding the impact
f menopause on women’s health is thus becoming increas-
ngly important.
See page 1976
Determinants of age at menopause are incompletely
nderstood. The age at menopause correlates between
others and daughters and between sisters. A study of twins
uggested 63% heritability of menopausal age (4). A com-
on polymorphism in the estrogen receptor alpha has been
ssociated with earlier onset of menopause, as has the Factor
Leiden mutation (5,6). Smoking is the only environmen-
al factor that has been consistently associated with earlier
enopause (7).
Although it is clear that coronary heart disease (CHD)
ncidence and prevalence are higher in postmenopausal
ompared with premenopausal women, the impact of
enopause and loss of endogenous estrogen distinct from
hat of advancing age remains controversial. Perimeno-
ausal metabolic changes seen in longitudinal studies are
eminiscent of the metabolic syndrome (8). Despite these
dverse changes in the cardiovascular risk profile, CHD
ortality rates do not accelerate at or after natural meno-
ause, and the apparent increase in CHD risk among
omen with premature natural menopause seems to be
econdary to confounding by smoking (9–11). Serum levels
f endogenous sex hormones do not correlate with severity
*Editorials published in the Journal of American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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as served as consultant for Pfizer, Reliant, and CV Therapeutics.f atherosclerosis or coronary events, and attempts to
harmacologically replace estrogens in postmenopausal
omen have not improved coronary morbidity or mortality
9,12–14).
Kok et al. (15), in a very provocative paper in this issue of
he Journal, suggest that it is not menopause that adversely
ffects cardiovascular risk but rather that cardiovascular risk
actors determine the age at menopause, possibly by induc-
ng ischemic damage in the ovaries or through direct effects
n the endocrine system. The authors analyzed data on 695
remenopausal women in the Framingham cohort who
eached natural menopause during the study. With serial
ata obtained at the biannual exams, the authors estimated
he values of total cholesterol, relative weight, and blood
ressure at age 43 through linear regression models for each
articipant and determined whether each risk factor had
ncreased, decreased, or remained the same during the
remenopausal years. Framingham risk score was estimated
n a subset of women at age 35 years with an assumed
ormal high-density lipoprotein (HDL) cholesterol level.
nalyses were adjusted for smoking status at the exam
losest to menopause.
Mean menopausal age was 49.9 years, approximately 1.5
ears earlier than reported for the U.S. population (2),
ossibly due to the very high smoking rate of 42% in this
tudy. Earlier age at menopause was associated with higher
holesterol levels at age 43 years, increase in cholesterol and
lood pressure before menopause, and both increases and
ecreases in relative weight. Improvements in cholesterol
nd systolic blood pressure were associated with a later
enopause. A 1% higher 10-year risk for CHD at age 35
ears was associated with a decrease in menopausal age of
1.8 years (95% confidence interval 2.72 to 0.92).
A major strength of the current study is the use of
rospectively collected longitudinal risk-factor data and
odeling that allowed estimation of risk factors at a specific
ge, thus permitting an analysis not confounded by age.
ecause of the frequency of exams, the authors were also
ble to determine age at cessation of menstruation quite
ccurately and distinguish between natural and surgical
enopause, excluding the latter from this analysis. What is
ess clear, however, is that cessation of menstruation at
ounger ages in this cohort necessarily represented “meno-
ause.” It is likely that some of the younger women had
econdary amenorrhea and some might have had hypotha-
amic hypoestrogenemia, a condition that has been associ-
ted with angiographic coronary disease among women
ndergoing diagnostic angiography for suspected myocar-
ial ischemia (16).
The authors assume in their modeling that the relation-
hip between cholesterol and menopausal age is linear
hroughout the range of values measured. If serum choles-
erol adversely influences ovarian function through vascular
njury, an exponential model analogous to the relationship
etween cholesterol and CHD might have been more
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May 16, 2006:1984–6 Editorial Commentppropriate. Similar concerns apply to the other risk-factor
elationships. Although estimating Framingham risk with
ssumed “normal” HDL cholesterol levels is not ideal, this
s unlikely to have had a major impact, because Framingham
isk estimates for a 35-year-old woman are relatively
nsensitive to the HDL cholesterol levels entered into the
quations.
In the U.S., cardiovascular risk-factor prevalence in-
reases with advancing age. In this Framingham cohort,
holesterol decreased in 15% of women, weight in 14%, and
ystolic blood pressure in 24% despite advancing age and in
he absence of pharmacologic therapy. Such spontaneous
nd unexplained “risk-factor improvement” raises concern
bout underlying diseases that could have confounded the
elationship to menopausal age. Even if the changes were
ue to improvement in diet and/or physical activity level,
onfounding is still a possibility, because the reason for the
ifestyle change could have been related to age at meno-
ause. Such confounding might explain the puzzling finding
hat both increases and decreases in relative weight related
o earlier age at menopause.
Prevalence of cardiovascular risk factors varies widely by
ountry. If risk factors have a substantial influence on age at
enopause, one would expect the same between-country
eterogeneity in menopausal ages as in risk-factor preva-
ence and in CHD morbidity and mortality. Cross-cultural
omparisons of menopausal age suggest that average age at
enopause is not highly variable. The range of average age
t menopause reported among almost 19,000 women in 11
ountries in Europe, the Americas, Asia, Australia, and
frica was only 49 to 52 years (mean 50 years) (17). A study
onducted in menopausal women in seven Southeast Asian
ountries similarly revealed a median age at menopause of
1 years (18). Secular trends might also provide information
bout the relationship of cardiovascular risk factors and
enopausal age. McKinlay et al. (19) tabulated results from
3 studies conducted in Europe and the U.S. between the
960s and 1980s and did not find significant differences in
verage menopausal age between countries or between time
eriods. Historical reviews have even suggested that average
ge at menopause has not changed since antiquity (20).
hile ecologic comparisons such as these have significant
imitations and do not rule out a causal relationship between
ardiovascular risk factors and menopausal age in an indi-
idual woman, the lack of heterogeneity in menopausal ages
cross markedly different cardiovascular risk environments
uggests, however, that the effect of cardiovascular risk
actors on menopausal age is at most modest.
The Stages of Reproductive Aging Workshop (STRAW)
istinguished three reproductive stages (early, peak, late),
wo stages of menopausal transition (early, late), and two
ostmenopausal stages (early, late) (21). The late reproduc-
ive stage that is characterized by fertility decline and
rogressive hormonal changes generally falls into the fourth
ecade of life around age 35 years and beyond (i.e., typically
0 to 15 years before the final menstrual period). Vasomotor
1ymptoms and other symptoms generally attributed to
enopause might start in this late reproductive stage as
ell, suggesting that changes in the hypothalamic-pituitary-
varian axis have a physiologic impact beyond the repro-
uctive system. The risk-factor trends calculated by Kok
t al. (15) are based on an average of 4.9 measurements
range 2 to 10) before menopause, corresponding to an
verage of 10 years of observation before the final menstrual
eriod (range 4 to 20 years). These risk-factor trends were thus
easured in the late reproductive phase (i.e., at a time when
ndocrine changes in the reproductive system were already
n progress). We do not know whether endocrine changes
nd risk-factor changes simply occurred concurrently,
hether risk-factor changes influenced the endocrine
hanges in progress and thus changed menopausal age as the
uthors hypothesize, or whether endocrine changes caused
oth a change in risk-factor levels over time and determined
enopausal age.
Although the hypothesis put forward by Kok et al. (15) is
ntriguing, the current study design cannot provide a defin-
tive answer. Longitudinal studies such as the Study of
omen’s Health Across the Nation (SWAN) (22), which
ollect detailed demographic and clinical data, data on
ardiovascular risk factors, health behaviors, and psychoso-
ial factors as well as serial markers of ovarian function, will
e in a better position to further our understanding of the
elationship between cardiovascular risk and menopause.
eprint requests and correspondence: Dr. Vera Bittner, LHRB
10 –UAB Station, Birmingham, Alabama 35294. E-mail:
bittner@uab.edu.
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